Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
- Revenue in EUR (TTM)1.29bn
- Net income in EUR-301.35m
- Incorporated2008
- Employees1.15k
- Locationargenx SELaarderhoogtweg 25AMSTERDAM 1101 EBNetherlandsNLD
- Phone+31 763030
- Websitehttps://www.argenx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BACHEM HOLDING AG | 596.79m | 115.63m | 6.57bn | 2.01k | 56.50 | 4.81 | 40.45 | 11.00 | 1.50 | 1.50 | 7.73 | 17.61 | 0.3765 | 1.23 | 3.33 | 287,794.60 | 7.29 | 8.85 | 8.17 | 10.28 | 30.65 | 31.63 | 19.38 | 19.74 | 3.04 | 29.80 | 0.0003 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
Zealand Pharma A/S | 46.15m | -99.04m | 8.09bn | 270.00 | -- | 18.66 | -- | 175.31 | -12.52 | -12.52 | 5.78 | 45.56 | 0.1397 | 4.18 | 2.86 | 1,360,664.00 | -29.99 | -42.74 | -32.82 | -50.24 | 90.07 | 96.13 | -214.60 | -464.66 | 12.28 | -- | 0.1206 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
Qiagen NV | 1.78bn | 309.77m | 8.52bn | 5.90k | 28.06 | 2.63 | 17.02 | 4.78 | 1.38 | 1.38 | 7.97 | 14.78 | 0.3209 | 1.84 | 5.64 | 298,708.00 | 5.58 | 5.41 | 6.63 | 6.53 | 62.78 | 64.65 | 17.38 | 16.35 | 1.45 | -- | 0.2946 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
Genmab A/S | 2.38bn | 730.79m | 16.42bn | 2.29k | 22.36 | 3.71 | -- | 6.89 | 82.80 | 82.80 | 269.74 | 498.87 | 0.5297 | -- | 4.51 | 8,059,438.00 | 16.25 | 17.43 | 17.48 | 18.59 | 74.05 | -- | 30.69 | 35.87 | 12.42 | -- | 0.0301 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
argenx SE | 1.29bn | -301.35m | 25.60bn | 1.15k | -- | -- | -- | 19.77 | -5.20 | -5.20 | 22.34 | -- | -- | -- | -- | 1,127,731.00 | -- | -17.65 | -- | -19.79 | 89.87 | -- | -23.28 | -97.72 | -- | -- | -- | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
Lonza Group AG | 6.94bn | 676.06m | 38.65bn | 18.00k | 58.38 | 3.95 | 30.42 | 5.57 | 8.87 | 8.87 | 91.16 | 131.07 | 0.3928 | 2.80 | 5.84 | 373,166.70 | 3.83 | 5.07 | 4.64 | 6.21 | 29.00 | 39.15 | 9.75 | 14.52 | 1.20 | 11.86 | 0.2275 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
Holder | Shares | % Held |
---|---|---|
Baillie Gifford & Co.as of 20 May 2024 | 2.95m | 4.97% |
Schroder Investment Management Ltd.as of 30 Apr 2024 | 2.39m | 4.02% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 2.08m | 3.50% |
Wellington Management Co. LLPas of 24 Jun 2024 | 1.82m | 3.06% |
Norges Bank Investment Managementas of 15 Jul 2024 | 1.73m | 2.91% |
BlackRock Fund Advisorsas of 04 Jul 2024 | 1.16m | 1.96% |
Federated Global Investment Management Corp.as of 31 Mar 2024 | 872.25k | 1.47% |
Bellevue Asset Management AGas of 31 Mar 2024 | 770.00k | 1.30% |
BlackRock Advisors (UK) Ltd.as of 04 Jul 2024 | 513.16k | 0.86% |
Polar Capital LLPas of 31 May 2024 | 427.29k | 0.72% |